Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review
The need for ongoing monitoring for TMA throughout carfilzomib therapy, regardless of treatment duration, is emphasized. Early diagnosis and intervention, including drug discontinuation and the timely initiation of PEX, are crucial for patient recovery.
Authors
- György Sinkovits (ORCID: https://orcid.org/0000-0002-5355-7318)
- Ágnes Király
- Mónika Fekete (ORCID: https://orcid.org/0000-0001-8632-2120)
- Zoltán Prohászka (ORCID: https://orcid.org/0000-0003-1761-7982)
- Bálint Gergely Szabó (ORCID: https://orcid.org/0000-0003-1775-1356)
- Ágnes Szilágyi (ORCID: https://orcid.org/0000-0002-9769-3215)
- Andrea Várkonyi
- Gábor Mikala (ORCID: https://orcid.org/0000-0003-2204-7398)
- Andrea Ceglédi (ORCID: https://orcid.org/0000-0002-4285-7518)
- Hajnalka Andrikovics (ORCID: https://orcid.org/0000-0002-8368-9784)
- Zsuzsanna Szemlaky
- Szabolcs Tasnády (ORCID: https://orcid.org/0000-0002-6736-3493)
- Marienn Réti (ORCID: https://orcid.org/0000-0002-4682-5628)
Institutions
- Semmelweis University (HU)
- National Center for Epidemiology (HU)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2024-12-20
- DOI
- https://doi.org/10.3390/ph17121722
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.91